home / stock / autl / autl news

AUTL News and Press, Autolus Therapeutics plc From 11/15/23

Stock Information
Company Name: Autolus Therapeutics plc
Stock Symbol: AUTL
Market: NASDAQ
Website: autolus.com
Menu
AUTL AUTL Quote AUTL Short AUTL News AUTL Articles AUTL Message Board
Get AUTL Alerts

News, Short Squeeze, Breakout and More Instantly...
AUTL - Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension with obe-cel, as well as initial data from the AUTO8 M...
AUTL - Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript

2023-11-03 22:05:03 ET Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial O...

AUTL - Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

obe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II study AUTO8: oral presentation of MCARTY Phase I Study obe-cel: poster presentation - pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension obe-cel: poster presen...

AUTL - Autolus Therapeutics GAAP EPS of -$0.26 in-line

2023-11-02 07:22:24 ET More on Autolus Therapeutics Autolus: CAR-T Therapy Looks Promising Autolus Therapeutics: Innovating T Cell Cancer Treatments Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Autolu...
AUTL - Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Updated clinical data at the Ame...

AUTL - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

AUTL - Expected earnings - Autolus Therapeutics plc

Autolus Therapeutics plc (AUTL) is expected to report $-0.24 for Q3 2023
AUTL - Autolus Therapeutics Q3 2023 Earnings Preview

2023-11-01 12:51:31 ET More on Autolus Therapeutics Autolus: CAR-T Therapy Looks Promising Autolus Therapeutics: Innovating T Cell Cancer Treatments Seeking Alpha’s Quant Rating on Autolus Therapeutics Historical earnings data for Autolus Therapeutics ...

AUTL - MLCO, GRIN and ADTN are among after hour movers

2023-10-18 17:39:01 ET Gainers: Netflix ( NFLX ) +12% . Melco Resorts & Entertainment  ( MLCO ) +5% . ADTRAN Holdings ( ADTN ) +4% . Acumen Pharmaceuticals ( ABOS ) +4% . Gracell Biotechnologies  ( GRCL ) +4% . ...

AUTL - Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to ...
Previous 10 Next 10